

Strategic Research & Innovation Committee

minutes

Minutes of the Strategic Research & Innovation meeting held on 12th September 2023

Present:	Bob Burgoyne	Non-Executive Director (Chair)
	Louise Robson	Non-Executive Director
	Prof Jay Wright	Clinical Lead for Research and Director of Research & Innovation
	Karen Edge	Chief Finance Officer
	Prof Reecha Sofat	Head of Department Pharmacology and Therapeutics, University of Liverpool
	Keith Wilson	Patient Research Ambassador
	Catarina Teige	Interim Deputy Director of Research & Innovation
	Carole Spencer	Director of System Partnerships at the Innovation Agency
	Jonathan Develing	Director of Strategic Partnerships
	Jennifer Crooks	Deputy Director of Research & Innovation
In Attendance:	Ellis Hayes	Director of Operations, Medicine
	Anne-Marie Davies	Associate Non-Executive Director (Observing)
	Jennifer Ohlsson	Senior Executive Assistant (Minutes)
Apologies for Absence:	Jane Tomkinson	Chief Executive Officer
	Prof Raphaela Kane	Pro Vice Chancellor, Faculty of Health, LJMU
	Jonathan Mathews	Chief Operating Officer

1. Apologies for Absence

Apologies noted above.

2. Declarations of Interest

No declarations of Interest noted at this meeting.

Action

3. Minutes of the previous meeting on 18th July 2023

It was agreed to amend the paragraph below in the minutes from the 18th July to the below:

'Keith Wilson, Patient Research Ambassador thanked colleagues for listening to concerns over the Research Unit being used for purposes other than research and appreciates the positive response from the Chief Executive and Chair'.

Minutes of the previous meeting were agreed as an accurate record of the meeting providing the above changes were made.

4. Action log

Action 1: Update on the implementation plan due in February 2024.

Action 2: Update on the innovation agenda on the agenda for discussion. Action closed.

5. LCCS review update

JW provided an update on the LCCS review and noted that there was a recent meeting of the three partners, with representatives from University of Liverpool, LHCH and John Moores to discuss where things are and it was agreed that the partners will continue to meet.

JW informed colleagues that Jenny Crooks, Deputy Director of Research and Innovation, is going to write some new terms of reference for LCCS and added that all three partners are very committed. It was noted that there needs to be very clear KPIs and the main issue was around governance.

JW noted that the LCCS Strategic Committee would meet every two months initially and will report back here to this Strategic Research and Innovation Committee as part of the LHCH governance and the similar through the University of Liverpool and John Moore's University.

JW also noted that the meeting involved a very frank discussion and there are major concerns from all three partners around the KPIs, the benefit for patients, the key focus on themes and the governance structure, so quite a lot of work needs to be redone in restructuring LCCS.

JC added that a scoping paper will also be done, alongside a Terms of Reference.

6. Partnership working and updated from partners

RS provided an update on the BHF bid and noted that three themes have been identified. Themes include; data science and a platform for research, AF and prevention and inequalities in health outcomes for women. This has been split into core and flexible funding.

Comments and questions were welcomed, and chair noted that this is an application for centre of excellence, but the anticipation is that this is converted into a development grant.

JW stated that there are more themes involved and added that the three themes are appropriate. JW also raised the potential future financial support highlighted in the supporting letter and added that this will be reviewed for senior executive input.

LR agreed that it is good to hear about the three themes, reflecting on previous discussion regarding themes and queried how the bids would work on a national perspective. RS noted that established centre of excellence tend to build on their expertise in cardiovascular care and added strengths should be built on and the bids should include how they would feed into NHS priorities.

JW raised the restructuring of LHP and informed colleagues that the Spark facility will now be renamed as a joint Research Office and Margaret Perez-Casal is now leading on this and there is a lot of input from the Research Directors in the city.

7. Research news and key successes

Reecha Sofat informed colleagues of a recently awarded NIHR Research Professorship.

JW informed colleagues of an international study looking at AF detected through pacemakers. There is hope that the results will be presented at the AHA and a paper has been submitted to the New England journal.

8. Report on Innovation Agenda

CS provided an update on the innovation agenda and reminded colleagues of the project objectives. CS noted that the innovation agenda is on schedule and noted that initial work found that the Trust was found to be very innovative overall.

The vision is to harness collective expertise to explore new ways of working and to adopt innovation, innovative thinking and design to enhance drive for excellence.

The aim is to actively seek out innovative change to enable continuous progress in delivery of high-quality patient experience, excellent outcomes and safe care.

Comments and questions were welcomed, and JC noted concern on how this will be managed and facilitated and added that the governance is the key to getting this right and making this work.

LR noted that it was helpful to see the innovation update and suggested the consideration of a digital innovation portal for ideas for logging and filtering ideas. LR also noted the continuum from continuous improvement to innovation transformation and where the different ideas land and added that a coordination piece is essential.

LR also noted the culture of adoption and scaling and added that there is lots of good work to be done and shifting the dial on this culture will be really important.

KE noted that there are many activities that are currently being done that are innovative and it is important how this is captured and organised, so that it does not blur into other fields such as QI, activity improvement, project management and CIP. It is important that this does not become more disjointed with how the Trust organises and it would be good to think of this in light of the work already being done operationally.

JC stated that there needs to be agreement of what the priorities are for the Trust. JC also raised collaborative work and suggested that there need to be a further look at the other partners.

Chair noted that importance of the leadership and management of this and added the key issue would be to identify someone at Trust level to lead on this.

CS confirmed that an update will be taken to the Strategy Day and an update will also be taken to Board of Directors in the Autumn 2023.

Chair thanked CS for all the hard work done.

9. Minutes from the last operational R&I Committee

Strategic R&I Colleagues were asked to note the minutes from the Operational R&I Committee from 9th June 2023

There were no further comments or questions.

10. Strategic R&I business cycle

Strategic R&I Committee colleagues were asked to note the business cycle and this was approved by the committee.

Date and time of next meeting:

Tuesday 12th December 2023, 3.00pm – 4.30pm, MS Teams